136 related articles for article (PubMed ID: 18211048)
1. Novel hierarchical classification and visualization method for multiobjective optimization of drug properties: application to structure-activity relationship analysis of cytochrome P450 metabolism.
Yamashita F; Hara H; Ito T; Hashida M
J Chem Inf Model; 2008 Feb; 48(2):364-9. PubMed ID: 18211048
[TBL] [Abstract][Full Text] [Related]
2. Visualization of large-scale aqueous solubility data using a novel hierarchical data visualization technique.
Yamashita F; Itoh T; Hara H; Hashida M
J Chem Inf Model; 2006; 46(3):1054-9. PubMed ID: 16711724
[TBL] [Abstract][Full Text] [Related]
3. Automated information extraction and structure-activity relationship analysis of cytochrome P450 substrates.
Yamashita F; Feng C; Yoshida S; Itoh T; Hashida M
J Chem Inf Model; 2011 Feb; 51(2):378-85. PubMed ID: 21247177
[TBL] [Abstract][Full Text] [Related]
4. Classification of cytochrome p(450) activities using machine learning methods.
Hammann F; Gutmann H; Baumann U; Helma C; Drewe J
Mol Pharm; 2009; 6(6):1920-6. PubMed ID: 19813762
[TBL] [Abstract][Full Text] [Related]
5. Modeling of human cytochrome p450-mediated drug metabolism using unsupervised machine learning approach.
Korolev D; Balakin KV; Nikolsky Y; Kirillov E; Ivanenkov YA; Savchuk NP; Ivashchenko AA; Nikolskaya T
J Med Chem; 2003 Aug; 46(17):3631-43. PubMed ID: 12904067
[TBL] [Abstract][Full Text] [Related]
6. Probing small-molecule binding to cytochrome P450 2D6 and 2C9: An in silico protocol for generating toxicity alerts.
Rossato G; Ernst B; Smiesko M; Spreafico M; Vedani A
ChemMedChem; 2010 Dec; 5(12):2088-101. PubMed ID: 21038340
[TBL] [Abstract][Full Text] [Related]
7. Predicting drug metabolism: a site of metabolism prediction tool applied to the cytochrome P450 2C9.
Zamora I; Afzelius L; Cruciani G
J Med Chem; 2003 Jun; 46(12):2313-24. PubMed ID: 12773036
[TBL] [Abstract][Full Text] [Related]
8. Identification of cytochrome P450 2D6 and 2C9 substrates and inhibitors by QSAR analysis.
Jónsdóttir SÓ; Ringsted T; Nikolov NG; Dybdahl M; Wedebye EB; Niemelä JR
Bioorg Med Chem; 2012 Mar; 20(6):2042-53. PubMed ID: 22364953
[TBL] [Abstract][Full Text] [Related]
9. Structure-based methods for the prediction of the dominant P450 enzyme in human drug biotransformation: consideration of CYP3A4, CYP2C9, CYP2D6.
Manga N; Duffy JC; Rowe PH; Cronin MT
SAR QSAR Environ Res; 2005; 16(1-2):43-61. PubMed ID: 15844442
[TBL] [Abstract][Full Text] [Related]
10. MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist.
Cruciani G; Carosati E; De Boeck B; Ethirajulu K; Mackie C; Howe T; Vianello R
J Med Chem; 2005 Nov; 48(22):6970-9. PubMed ID: 16250655
[TBL] [Abstract][Full Text] [Related]
11. Recursive partitioning for the prediction of cytochromes P450 2D6 and 1A2 inhibition: importance of the quality of the dataset.
Burton J; Ijjaali I; Barberan O; Petitet F; Vercauteren DP; Michel A
J Med Chem; 2006 Oct; 49(21):6231-40. PubMed ID: 17034129
[TBL] [Abstract][Full Text] [Related]
12. Novel approach to predicting P450-mediated drug metabolism: development of a combined protein and pharmacophore model for CYP2D6.
de Groot MJ; Ackland MJ; Horne VA; Alex AA; Jones BC
J Med Chem; 1999 May; 42(9):1515-24. PubMed ID: 10229622
[TBL] [Abstract][Full Text] [Related]
13. Validation of model of cytochrome P450 2D6: an in silico tool for predicting metabolism and inhibition.
Kemp CA; Flanagan JU; van Eldik AJ; Maréchal JD; Wolf CR; Roberts GC; Paine MJ; Sutcliffe MJ
J Med Chem; 2004 Oct; 47(22):5340-6. PubMed ID: 15481972
[TBL] [Abstract][Full Text] [Related]
14. A quantitative structure-activity relationship analysis on a series of alkyl benzenes metabolized by human cytochrome p450 2E1.
Lewis DF; Sams C; Loizou GD
J Biochem Mol Toxicol; 2003; 17(1):47-52. PubMed ID: 12616646
[TBL] [Abstract][Full Text] [Related]
15. [Features of the metabolism of various drugs involving cytochrome P-450 isoenzymes].
Filimonova AA; Ziganshin AU; Ziganshina LE
Eksp Klin Farmakol; 2007; 70(3):69-77. PubMed ID: 17650639
[TBL] [Abstract][Full Text] [Related]
16. Human CYPs involved in drug metabolism: structures, substrates and binding affinities.
Lewis DF; Ito Y
Expert Opin Drug Metab Toxicol; 2010 Jun; 6(6):661-74. PubMed ID: 20402561
[TBL] [Abstract][Full Text] [Related]
17. CYP2C9 structure-metabolism relationships: optimizing the metabolic stability of COX-2 inhibitors.
Ahlström MM; Ridderström M; Zamora I; Luthman K
J Med Chem; 2007 Sep; 50(18):4444-52. PubMed ID: 17696334
[TBL] [Abstract][Full Text] [Related]
18. Importance of hydrophobic parameters in identifying appropriate pose of CYP substrates in cytochromes.
Ramesh M; Bharatam PV
Eur J Med Chem; 2014 Jan; 71():15-23. PubMed ID: 24269512
[TBL] [Abstract][Full Text] [Related]
19. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
Zhou SF; Liu JP; Chowbay B
Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
[TBL] [Abstract][Full Text] [Related]
20. Cocktail-substrate assay system for mechanism-based inhibition of CYP2C9, CYP2D6, and CYP3A using human liver microsomes at an early stage of drug development.
Mori K; Hashimoto H; Takatsu H; Tsuda-Tsukimoto M; Kume T
Xenobiotica; 2009 Jun; 39(6):415-22. PubMed ID: 19480547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
